Incyte says under-the-radar JAK inhibitor clears a high bar for skin disorder
Incyte — the company behind Jakafi and Olumiant — wants to put a third JAK inhibitor on the map.
Presenting at the European Hidradenitis Suppurativa Foundation conference, the biotech highlighted long-term data from a Phase II trial testing povorcitinib as a treatment for hidradenitis suppurativa (HS), a skin condition characterized by painful nodules and abscesses.
If the results hold up in Phase III, the drug may “establish a new high water mark for efficacy,” Cowen analyst Marc Frahm wrote in a note, even as it goes against AbbVie’s Humira and Novartis’ Cosentyx.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.